Literature DB >> 11746849

Experimental treatment of chronic Trypanosoma cruzi infection in mice with 2-n-propylquinoline.

H Nakayama1, M E Ferreira, A Rojas de Arias, N Vera de Bilbao, S Torres, A Schinini, A Fournet.   

Abstract

It was reported previously that 2-n-propylquinoline was active against the epimastigote form of Trypanosoma cruzi. The effects of oral treatments with benznidazole and 2-n-propylquinoline were evaluated in Balb/c mice infected with T. cruzi chronically. The reference drug and 2-n-propylquinoline were administered 60 days post-infection for 30 days at 25 mg/mL. At 35 days post-treatment, the serological tests (ELISA) of the 2-n- propylquinoline-treated mice were significantly different from the controls (p = 0.01) and the benznidazole-treated mice (p = 0.03), while this was not the case at 85 days post-treatment. These results are encouraging for continuing the investigation of other analogues of 2-n-propylquinoline in experimental chronic Chagas' disease. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746849     DOI: 10.1002/ptr.877

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  2 in total

1.  Trypanosoma cruzi infection: do distinct populations cause intestinal motility alteration?

Authors:  Monica de Melo Medeiros; Tania C Araújo-Jorge; Wanderson S Batista; Tshaca Mahatma Oara Alves da Silva; Andréa Pereira de Souza
Journal:  Parasitol Res       Date:  2010-05-08       Impact factor: 2.289

2.  Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.

Authors:  Hector Nakayama; Philippe M Loiseau; Christian Bories; Susana Torres de Ortiz; Alicia Schinini; Elsa Serna; Antonieta Rojas de Arias; Mohamed A Fakhfakh; Xavier Franck; Bruno Figadère; Reynald Hocquemiller; Alain Fournet
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.